Interferon News and Research

RSS

Antiviral inhibitor DDX42 shows broad activity against Chikungunya, HIV and SARS-CoV-2

By exploiting type 1 interferon's ability to foster an antagonistic cellular environment for viral replication, a research group from France pinpointed DEAD-box RNA helicase DDX42 as an intrinsic inhibitor of HIV, but also other pathogenic viruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Chikungunya virus.

29 Oct 2020

Research shows why certain people infected with COVID-19 show no symptoms

Researchers worldwide have been surprised to see that individuals can be infected with the SARS-CoV-2 virus - the virus that produces COVID-19 - without showing symptoms. Since these individuals expose others to infection without knowing it, it is important to find an explanation and hopefully a solution to this.

29 Oct 2020

Gut's immune response to SARS-CoV-2 very different from the lung

Megan L. Stanifer et al. study the immune response in the human gut upon SARS-CoV-2 infection. The study published as a bioRxiv* preprint reveals a robust proinflammatory response: a cell type-specific or a tissue-specific regulation of interferon-mediated signaling during SARS-CoV-2 infection.

27 Oct 2020

Inflammasome may play a key role in triggering immune response to cancer

The inflammasome — a protein signaling network that is activated to rid the body of virus or bacteria-infected cells — may play an important role in triggering an immune response to cancer and causing an existing class of drugs to work better against cancers.

27 Oct 2020

Study: SARS-CoV-2 virus adopts new strategy to ensure its replication, spread

Since COVID-19 began its menacing march across Wuhan, China, in December 2019, and then across the world, the SARS-CoV-2 virus has taken a "whatever works" strategy to ensure its replication and spread.

27 Oct 2020

Study reveals human protein that helps the immune system fight viral infections

University of North Carolina School of Medicine scientists has made a curious discovery about a well-known human protein that helps the immune system fight viral infections.

27 Oct 2020

Lung biomarkers may predict severe COVID-19

Two University of New Mexico researchers postulate certain specific biomarkers' relevance in predicting the potential for progression to severe COVID-19 in a paper published on the preprint server bioRxiv*

27 Oct 2020

Cellular senescence variations may control health and onset of age-related diseases

Researchers from Kumamoto University, Japan have proposed that cellular senescence variations during the aging process could lead to control of health and onset of age-related diseases.

27 Oct 2020

Researchers develop lab-grown lung model to study SARS-CoV-2 infection

A team of Duke University researchers has developed a lab-grown living lung model that mimics the tiny air sacs of the lungs where coronavirus infection and serious lung damage take place.

23 Oct 2020

Vitamin C and COVID-19: A Review

In a recent review published in Preprints*, Patrick Holford et al. address vitamin C's role as adjunctive therapy for respiratory infection, sepsis, and COVID-19.

23 Oct 2020

Researchers assess molecular basis of SARS-CoV-2 severity and poor outcomes in lung disease

A recent study published on the preprint server bioRxiv in October 2020 shows that in patients with chronic lung disease, the pattern of gene expression in the different types of cell changes such that the lung epithelium is prepared to tackle SARS-CoV-2 infection. Also, the altered gene programs have an impact on the immune response.

22 Oct 2020

Moffitt researchers find immune-oncologic differences in prostate tumors of African American men

Prostate cancer is the most common type of cancer among American men after skin cancer, but the disease does not affect all races equally.

21 Oct 2020

WHO study finds Remdesivir and other repurposed drugs ineffective in COVID-19

A large-scale randomized trial has recently been conducted by the World Health Organization (WHO) to evaluate the efficacy of four repurposed antiviral medicines, including Remdesivir, Hydroxychloroquine, Lopinavir, and Interferon, currently used to treat hospitalized coronavirus disease 2019 (COVID-19) patients.

18 Oct 2020

Control trial proves effectiveness of repurposed drugs for COVID-19 treatment

In just six months, the world's largest randomized control trial on COVID-19 therapeutics has generated conclusive evidence on the effectiveness of repurposed drugs for the treatment of COVID-19.

16 Oct 2020

Scientists discover a novel antiviral strategy for treating COVID-19

A research team led by Professor Hongzhe SUN, Norman & Cecilia Yip Professor in Bioinorganic Chemistry, Department of Chemistry, Faculty of Science, and Professor Kwok Yung YUEN, Henry Fok Professor in Infectious Diseases, Department of Microbiology, Li Ka Shing Faculty of Medicine of the University of Hong Kong (HKU), has discovered a novel antiviral strategy for treatment of COVID-19.

16 Oct 2020

Exposure to ancient parasites may be linked to humans’ response to coronavirus

Why are some people more resilient to viruses than others? The answer has eluded scientists for centuries and, in the age of COVID-19, has come to represent one of the holy grails of biomedical research.

16 Oct 2020

Mendelian randomization helps evaluate impact of circulating proteins in COVID-19

Researchers identify circulating proteins influencing COVID-19 susceptibility and severity by employing a large-scale two-sample Mendelian randomization (MR) study.

15 Oct 2020

Characterization of prognostic markers to predict COVID-19 severity

A team of scientists from the United Kingdom has revealed that markers of endothelial cell injury are associated with severe and fatal outcome of coronavirus disease 2019 (COVID-19). The study is currently available on the medRxiv* preprint server.

14 Oct 2020

SARS-CoV-2 infection of carotid arteries may explain vascular involvement in COVID-19

A new study published on the preprint server bioRxiv in October 2020 shows that the virus causing COVID-19, namely, SARS-CoV-2, produces replicative infection in the carotid arteries and affects the vascular responses. This could have a profound bearing on the understanding of the disease and its clinical treatment.

14 Oct 2020

Researchers identify molecular mechanisms of IFN responses in SARS-CoV-2 infection

As of October 2020, SARS-CoV-2 causes an ongoing pandemic, with more than 35 million reported cases and more than 1 million deaths worldwide. One prominent feature that distinguishes COVID-19 from SARS in terms of immune responses is the poor induction of a type I interferon (IFN) response by SARS-CoV-2 compared to SARS-CoV and influenza A virus.

12 Oct 2020